Partner Headlines - ESRX

  1. EXPRESS SCRIPTS

    IBD
  2. UnitedHealth Beats Views, Sits Pretty As Rivals Merge

    IBD
  3. UnitedHealth Set For Q2 Earnings Amid Deal Chatter

    IBD
  4. Will Bill Ackman Go After Express Scripts Next?

    GuruFocus
  5. Acquisitions May Fuel Gilead Sciences' Winning Ways

    IBD
  6. Horizon Pharma Seen In Deal-Making Mode

    IBD
  7. McKesson Sees Healthy Growth In Prescription Drugs

    IBD
  8. David Rolfe Adds to Most Valuable Stakes in His Portfolio

    GuruFocus
  9. Regeneron/Sanofi Cholesterol Drug Wins FDA Panel Vote

    IBD
  10. Gilead Nears Buy Zone On Healthy Drug Trial Results

    IBD
  11. Why Diplomat Pharmacy Gains Since IPO Look So Healthy

    IBD
  12. Horizon Pharma Survives Through Transformation

    IBD
  13. Morning Market Losers

    Benzinga
  14. Benzinga's Top Downgrades

    Benzinga
  15. Raymond James Downgrades Express Scripts Holding To Market Perform

    Benzinga
  16. Dodge & Cox Keeps Buying Express Scripts

    GuruFocus
  17. Pay-For-Performance Medicine

    Benzinga
  18. Making Money With Charles Payne: 05/26/15

    FoxBusiness
  19. Horizon Pharma Up On Bullish Leerink Initiation

    IBD
  20. CVS Health Buys Omnicare, Citing 'Long-Term' Benefits

    IBD
  21. Drug 'super spending' soars

    IBD
  22. 20 Questions With David Rolfe Part I

    GuruFocus
  23. Addiction Care Provider AAC Eyes National Brand

    IBD
  24. Medivation, Jazz Q1 Reports Miss; Regeneron Beats

    IBD
  25. Regeneron Q1 Earnings Beat As Eylea Research Pays Off

    IBD
  26. GoPro, Other Earnings Trigger Wild Price Swings

    IBD
  27. EXPRESS SCRIPTS

    IBD
  28. Express Scripts Posts In-Line Q1 Earnings, Issues Strong Forecast

    Benzinga
  29. Stocks Stumble To Early Losses; IPG Photonics Jumps

    IBD
  30. Why CVS Health And McKesson May Be Good Stock Picks

    IBD
  31. UnitedHealth Profit Soars On ObamaCare, Optum

    IBD
  32. UnitedHealth Up After Topping Views, Raising Outlook

    IBD
  33. UnitedHealth Eyes Biggest Earnings Gain In Years

    IBD
  34. Pioneer Fundamental Growth Fund: Why Is It Revving Up?

    IBD
  35. Horizon Pharma Soars On Q4 Beat, Guidance Raise

    IBD
  36. Catamaran EPS Tops, But Stock Falls On Weak Guidance

    IBD
  37. 10 Stocks You Should Be Watching Today

    Benzinga
  38. EXPRESS SCRIPTS

    IBD
  39. UPDATE: Express Scripts Tops Q4 Expectations, Shares Rise After ...

    Benzinga
  40. Nasdaq Stretches Win Streak To 9 Days

    IBD
  41. Earnings Scheduled For February 23, 2015

    Benzinga
  42. Must Watch Stocks for Today

    Benzinga
  43. Stocks Cap Short Week With Gains; Salix Up On Buyout Hopes

    IBD
  44. Rolfe Adds One Company to Portfolio in Fourth Quarter

    GuruFocus
  45. Analyzing Needham Growth Fund's Pick: Express Scripts (ESRX)

    GuruFocus
  46. Analyzing Needham Growth Fund's Pick: CarMax (KMX)

    GuruFocus
  47. Rite Aid Stock Soars, Steps Up Competition With CVS

    IBD
  48. Gilead Sciences Offering Fresh Wave Of Competition To AbbVie's ...

    GuruFocus
  49. Thornburg Value Fund Q4 2014 Commentary

    GuruFocus
  50. Gilead Q4 Earnings Beat, But Price War Taking Toll

    IBD
  51. Baird Remains Buyers Of Gilead Before Earnings Release

    Benzinga
  52. Cramer Gives His Opinion On Whole Foods Market, Whiting Petroleum ...

    Benzinga
  53. AmerisourceBergen Hits New High On Earnings, Outlook

    IBD
  54. Has Gilead Sciences Been Able To Maintain Its Lead Run In The ...

    GuruFocus
  55. Gilead, AbbVie Hepatitis C Price Cuts Will Hit Sales

    IBD
  56. Why Drug Pricing Could Bring Volatility To The Biotech Sector ...

    Benzinga
  57. Aetna Sides With Gilead In Hepatitis C Drug Battle

    IBD
  58. What The Market's Reading: An Iraq Ramp-Up & Biotech Moves

    Benzinga
  59. Steven Romick Buys 7 US and International Stocks in Q4

    GuruFocus
  60. Express Scripts Eyes New Price War: Anti-PCSK9 Drugs

    IBD
  61. Cholesterol Drug Costs Eyed

    IBD
  62. AbbVie Inc.'s Forthcoming Future Looks Optimistic

    GuruFocus
  63. Amgen's Decline May Be Linked To Comments Of Express Script's ...

    Benzinga
  64. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  65. AbbVie Stock Down After Guidance, Downgrade

    IBD
  66. Gilead Strikes Deal with CVS, Hits Back AbbVie

    GuruFocus
  67. Hepatitis Drugs Vie For Share

    IBD
  68. CVS Covering Gilead HCV Drugs, Countering AbbVie

    IBD
  69. Stocks Lose More Ground; Gilead Sciences Rises

    IBD
  70. CVS Picks Gilead Hep C Drugs As Price War Looms

    IBD
  71. Drug Distributor Reaps The Rewards Of Strategy Shift

    IBD
  72. Express Scripts Stock Dominated Q4; Which Funds Might've Won?

    Benzinga
  73. 5 Biotech Stocks With Big News Due In January

    IBD
  74. Stocks Hold Near Highs; LifeLock Breaks Out

    IBD
  75. Facebook Among IBD 50's Top 5 Earnings Kings In 2014

    IBD
  76. IBD 50: Biotechs Hammered, Then Find Support

    IBD
  77. First Pacific Advisors' Third-Quarter Investment in Yahoo! Increases ...

    GuruFocus
  78. Biotech Stocks Take A Beating, But Find Support

    IBD
  79. Stocks Score Small Gains; Virgin America Takes Flight

    IBD
  80. How Gilead And Johnson & Johnson's Tumble Affected These Hedge ...

    Benzinga
  81. Evercore ISI Analyst: 160,000 Patients Affected by AbbVie Hepatitis ...

    Benzinga
  82. Toys, Department Stores Rock, But Biotechs Tumble

    IBD
  83. Deutsche Bank Analyst Sees Gilead Sciences Vs. AbbVie 'Price ...

    Benzinga
  84. AbbVie Drug Displaces Gilead

    IBD
  85. Actavis, Valeant Largely Avoid Gilead's Hepatitis Dive

    IBD
  86. Express Scripts Picks AbbVie HCV Drugs Over Gilead

    IBD
  87. Express Scripts Knocks Gilead's Hepatitis C Drug in Favor of ...

    GuruFocus
  88. Bank Of America Downgrades Gilead Sciences, Sees Possible Pricing ...

    Benzinga
  89. Broad Indexes Little Changed; Facebook Breaks Out

    IBD
  90. Dow Outperforms While Nasdaq Holds Small Gain; Oil Weak

    IBD
  91. Express Scripts Picks AbbVie HCV Drugs Over Gilead

    IBD
  92. Mid-Morning Market Update: Markets Open Higher; Caesars Entertainment ...

    Benzinga
  93. Stocks Struggle To Hold Gains; Alaska Air, Spirit Up

    IBD
  94. Gilead Sciences Plummets Amid AbbVie Deal With Express Scripts

    Benzinga
  95. Stock Futures Point Higher; AbbVie Surges, Gilead Dives

    IBD
  96. AbbVie's Hep C Regimen OK'd, 12-Week Cost $83,319

    IBD
  97. How Can Drugmakers Handle New Pricing Pressures?

    IBD
  98. Are These Drugstore Retailers Good Investments?

    GuruFocus
  99. AmerisourceBergen a Key Player in the Pharma Industry

    GuruFocus
  100. Weekly 52-Week Highs Highlight: ITW, ESRX, TEVA, CHD, STI

    GuruFocus
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!